^
Association details:
Evidence:
Evidence Level:
Resistant: C3 ā€“ Early Trials
Source:
Title:

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Published date:
11/18/2020
Excerpt:
PPP2R2B expression showed marked downregulation in the relapsed metastatic tumors compared to the primary tumors (Pā€‰=ā€‰0.0035...), suggesting a correlation between PPP2R2B downregulation and trastuzumab resistance.
DOI:
10.1038/s41467-020-19704-x